Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

NEXT STORY
Turning Point Therapeutics to Host First Quarter 2021 Conference Call
PREV STORY
Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II

author_avatar
NASDAQ Market News

Argos Therapeutics Announces CEO Jeff Abbey Elected to NCBIO Board of Directors

DURHAM, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an ...

author_avatar
NASDAQ Market News

Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a ...

author_avatar
NASDAQ Market News